Skip to main content
. 2019 Nov 1;22(5):675–683. doi: 10.1093/neuonc/noz208

Fig. 3.

Fig. 3

Patients harboring LM from primary tumors with targetable mutations demonstrate improved overall survival. (A) Eighty-four of 171 patients (49%) harbored a targetable mutation. Patients with a targetable mutation had a significantly improved survival compared with those without a targetable mutation (log-rank P = 0.02). (B) Breakdown of specific mutation types among the 84 patients in this study with targetable mutations.